DOCSLIB.ORG

A Cell-Based NRG1-ERBB4 Assay Designed for High- Throughput Compound Screening to Identify Small Molecule Modulators with Relevance for Schizophrenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Cell-Based NRG1-ERBB4 Assay Designed for High- Throughput Compound Screening to Identify Small Molecule Modulators with Relevance for Schizophrenia A cell-based NRG1-ERBB4 assay designed for high- throughput compound screening to identify small molecule modulators with relevance for schizophrenia Dissertation for the award of the degree ‘Doctor rerum naturalium’ of the Georg-August-Universität Göttingen submitted by Wilko Hinrichs from Norderney, Germany Göttingen, 30.09.2012 Prof. Klaus-Armin Nave Ph.D. (Reviewer) Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen Prof. Dr. Martin Göpfert (Reviewer) Department of Cellular Neurobiology, Schwann-Schleiden Research Center, Göttingen Prof. Dr. André Fischer (Reviewer) Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen PD. Dr. Moritz Rossner Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen Prof. Dr. Thomas A. Bayer Department of Psychiatry, Division of Molecular Psychiatry, UKG Göttingen Dr. Judith Stegmüller Department of Cellular and Molecular Neurobiology, Max Planck Institute of Experimental Medicine, Göttingen Declaration Herewith I declare that I prepared the PhD thesis entitled:‘A cell-based NRG1- ERBB4 assay designed for high-throughput compound screening to identify small molecule modulators with relevance for schizophrenia' on my own and with no other sources and aids than quoted. 2 “We are as forlorn as children lost in the woods. When you stand in front of me and look at me, what do you know of the griefs that are in me and what do I know of yours. And if I were to cast myself down before you and weep and tell you, what more would you know about me than you know about Hell when someone tells you it is hot and dreadful? For that reason alone we human beings ought to stand before one another as reverently, as reflectively, as lovingly, as we would before the entrance to Hell.” Franz Kafka 3 Acknowledgments First, I want to thank my supervisor PD. Dr. Moritz Rossner, for the great PhD project, his support, and all his brilliant ideas and good advice accumulated in this thesis. Equally, I want to thank my co-supervisor Dr. Michael Wehr, for his friendship, for his patience, for the great discussions, the help with the projects, especially screening and biochemistry, and the proof reading of my thesis. Dr. Sven Wichert for the help with the Hamilton robot, all bioinformatical questions, and help with all computer-related problems. Dr. Magdalena Brzozka for discussions, help with the corrections and the deeper insight into mouse behavioural studies. Dr. Elena Ciirdaeva for great support with cloning and supplies of DNA. All members of the Rossner group and the Department of Neurogenetics, for friendship, help in all lab problems concerning techniques, instruments, software, and discussion of projects. The members of the Lead Discovery Centre Dortmund, particularly Dr. Sascha Menninger for the great co-operation, and a deeper insight into HTP screening, lead discovery, and lead optimisation The GGNB-CMPB program, specifically Prof Michael Hörner, for the fruit-full discussions and seminar series and the GGNB staff for the help with the administrative challenges. I am grateful for my PhD committee, including Prof. Martin Göpfert , and Prof. André Fischer, and especially Prof. Klaus-Armin Nave for discussions, encouragements, and having me as PhD student in his lab. Further thanks are to my parents, without there love, support and encouragement this thesis would not be possible. Carolin, for her love and support in this part of my life. All friends, fencers, and tabletop-wargamers for the life abroad the PhD. 4 Table of Content Acknowledgments ............................................................................................ 4 1 Summary .................................................................................................. 12 2 Introduction ............................................................................................. 13 2.1 General characterisation of schizophrenia ................................................... 13 2.3 Positive symptoms ...................................................................................... 15 2.4 Negative symptoms ..................................................................................... 15 2.5 Cognitive deficits ......................................................................................... 15 2.6 Comorbidities .............................................................................................. 16 2.7 Residual symptoms ..................................................................................... 17 2.8 History of schizophrenia .............................................................................. 18 2.9 Morphologic findings in schizophrenia ......................................................... 19 2.10 Genetic studies ............................................................................................ 20 2.10.1 DISC1 .................................................................................................. 21 2.10.2 NRG1-ERBB4 ...................................................................................... 22 2.11 Environmental factors .................................................................................. 23 2.12 Two hit hypothesis ....................................................................................... 23 2.13 Findings in animal models of schizophrenia ................................................ 24 2.13.1 Dopamine hypothesis of schizophrenia ................................................ 24 2.14 NRG1-ERBB4 animal models ...................................................................... 25 2.15 NRG1-ERBB4: from proteins to network analysis ........................................ 28 2.15.1 Why addressing the NRG1-ERBB4 signalling system? ........................ 28 2.15.2 Protein-protein-interactions and NRG1-ERBB4 signalling .................... 28 2.15.3 Neuregulin1 ......................................................................................... 29 2.15.4 ERBB receptor tyrosine kinase family .................................................. 31 2.15.5 NRG1-ERBB4 signalling in the nervous system ................................... 35 2.15.6 Adapters of ERBB receptors ................................................................ 35 2.15.7 PI3K..................................................................................................... 36 2.15.8 STAT5 ............................................................................................... 37 2.15.9 SHC1 ................................................................................................... 37 2.15.10 GRB2 ................................................................................................... 37 2.15.11 SRC ..................................................................................................... 37 2.16 Downstream pathways ................................................................................ 38 5 2.16.1 PI3K/ AKT pathway .............................................................................. 38 2.16.2 MAPK /ERK pathway ........................................................................... 38 2.17 Localisation of NRG1-ERBB4 signalling in the neuronal architecture .......... 40 2.17.1 Glutamate hypothesis of SZ ................................................................. 40 2.17.2 NMDA .................................................................................................. 40 mGLu2/3 40 2.17.3 Hyper- and hypo-frontality in SZ .......................................................... 41 2.17.4 From neuronal circuits to single synapses ........................................... 41 2.17.5 Alterations found in the neuronal circuit ............................................... 42 2.17.6 NRG1-ERBB4 in the development of PV+ interneurons ....................... 43 2.18 Targeting NRG1-ERBB4 with protein-protein interaction assays ................. 45 2.18.1.1 First generation drugs ...................................................................... 45 2.18.1.2 Second generation drugs ................................................................. 45 2.18.2 Classic hit to lead discovery ................................................................. 46 2.18.2.1 Compound screens .......................................................................... 47 2.19 Cell based assays ....................................................................................... 47 2.19.1 Biochemical methods e.g. Co-IP .......................................................... 47 2.19.2 Affinity columns ................................................................................... 47 2.20 Protein fragment complementation assays .................................................. 48 2.20.1 Yeast two hybrid .................................................................................. 48 2.21 Split TEV ..................................................................................................... 48 2.22 z’-Factor ...................................................................................................... 49 2.22.1 The interpretation of the z’-factor: ........................................................ 49 2.23 Aim of the thesis .......................................................................................... 50 3 Chemicals and Reagents ........................................................................ 51 3.1 Laboratory suplies ......................................................................................
Load more

Recommended publications
  • Gelred® and Gelgreen® Safety Report
    Safety Report for GelRed® and GelGreen® A summary of mutagenicity and environmental safety test results from three independent laboratories for the nucleic acid gel stains GelRed® and GelGreen® www.biotium.com General Inquiries: [email protected] Technical Support: [email protected] Phone: 800-304-5357 Conclusion Overview GelRed® and GelGreen® are a new generation of nucleic acid gel stains. Ethidium bromide (EB) has been the stain of choice for nucleic acid gel They possess novel chemical features designed to minimize the chance for staining for decades. The dye is inexpensive, sufficiently sensitive and very the dyes to interact with nucleic acids in living cells. Test results confirm that stable. However, EB is also a known powerful mutagen. It poses a major the dyes do not penetrate latex gloves or cell membranes. health hazard to the user, and efforts in decontamination and waste disposal ultimately make the dye expensive to use. To overcome the toxicity problem In the AMES test, GelRed® and GelGreen® are noncytotoxic and of EB, scientists at Biotium developed GelRed® and GelGreen® nucleic acid nonmutagenic at concentrations well above the working concentrations gel stains as superior alternatives. Extensive tests demonstrate that both used in gel staining. The highest dye concentrations shown to be non-toxic dyes have significantly improved safety profiles over EB. and non-mutagenic in the Ames test for GelRed® and GelGreen® dyes are 18.5-times higher than the 1X working concentration used for gel casting, and 6-times higher than the 3X working concentration used for gel staining. This Dye Design Principle is in contrast to SYBR® Safe, which has been reported to show mutagenicity At the very beginning of GelRed® and GelGreen® development, we made a in several strains in the presence of S9 mix (1).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • The Chem Access Project from Bitmap Graphics to Fully Accessible Chemical Diagrams
    The Chem Access project From Bitmap Graphics to Fully Accessible Chemical Diagrams Volker Sorge Scientific Document Analysis Group Progressive Accessibility Solutions School of Computer Science Birmingham, UK University of Birmingham progressiveaccess.com 9th European e-Accessibility Forum, 2015, Paris, 8 June 2015 Motivation I Accessibility to STEM material is important issue for inclusive education I Diagrams are an important teaching means in STEM I Chemical diagrams (depictions of molecules) are ubiquitous in teaching from GCSE and A-levels teaching to undergrad curriculum chemistry, biosciences, life sciences. I Previous work on assistive technology for chemical diagrams I Require diagrams to be drawn in particular way or authoring environment I Need for specialist software to access and interact with diagrams I Additional hurdles for both authors and readers Goals I Make regular teaching material accessible I From inaccessible image to support for independent learning I Source independence I Do not rely on the benevolent, educated author I Platform independence I Use standard web technology (HTML5) I Accessible with all browsers, screen readers I Provide a seamless user experience without/very little interface I Support diverse material, for novices and experts alike Examples I Different representations of Aspirin molecule. Displayed formula. Skeletal formula. Structural formula. Examples I Or somewhat more complex. Procedure Input: A bitmap image of a molecule diagram 1. Image analysis and recognition 2. Generation of annotated SVG
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • 11.2 Alkanes
    11.2 Alkanes A large number of carbon compounds are possible because the covalent bond between carbon atoms, such as those in hexane, C6H14, are very strong. Learning Goal Write the IUPAC names and draw the condensed structural formulas and skeletal formulas for alkanes and cycloalkanes. Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc. Naming Alkanes Alkanes • are hydrocarbons that contain only C—C and C—H bonds • are formed by a continuous chain of carbon atoms • are named using the IUPAC (International Union of Pure and Applied Chemistry) system • have names that end in ane • use Greek prefixes to name carbon chains with five or more carbon atoms Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc. IUPAC Naming of First Ten Alkanes Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc. 1 Condensed Structural Formulas In a condensed structural formula, • each carbon atom and its attached hydrogen atoms are written as a group • a subscript indicates the number of hydrogen atoms bonded to each carbon atom The condensed structural formula of butane has four carbon atoms. CH3—CH2—CH2—CH3 butane Core Chemistry Skill Naming and Drawing Alkanes Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc. Condensed Structural Formulas Alkanes are written with structural formulas that are • expanded to show each bond • condensed to show each carbon atom and its attached hydrogen atoms Expanded Condensed Expanded Condensed Chemistry: An Introduction to General, Organic, and Biological Chemistry, Twelfth Edition © 2015 Pearson Education, Inc.
    [Show full text]
  • International Journal of Current Advanced Research
    International Journal of Current Advanced Research ISSN: O: 2319-6475, ISSN: P: 2319-6505, Impact Factor: SJIF: 5.995 Available Online at www.journalijcar.org Volume 6; Issue 8; August 2017; Page No. 5172-5175 DOI: http://dx.doi.org/10.24327/ijcar.2017.5175.0665 Review Article MUSCLE RELAXANTS IN DENTISTRY - A REVIEW Vaishnavi Sivakali Subramanian* and Dhanraj Department of Prosthodontics, Saveetha Dental college and Hospitals, Chennai ARTICLE INFO ABSTRACT Article History: A muscle relaxant is a drug that affects skeletal muscle function and decreases the muscle tone. It may be used to alleviate symptoms such as muscle spasms, pain, and hyperreflexia. Received 13th May, 2017 th Muscle relaxants in dentistry are often used in treating temporomandibuar joint disorders. Received in revised form 14 A temporomandibular disorder (TMD) is a very common problem affecting up to 33% of June, 2017 Accepted 6th July, 2017 th individuals within their lifetime. TMD is often viewed as similar to musculoskeletal Published online 28 August, 2017 disorders of other parts of the body, therefore the treatment often involves similar principles as other regions as well. This review article includes brief description of Key words: commonly used muscle relaxants in dentistry, that describes mechanism of action, Dentistry, Temporomandibular Disorders, metabolism, dosage and side effects of the drug. muscle relaxants, muscle spasm. Copyright©2017 Vaishnavi Sivakali Subramanian and Dhanraj. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. INTRODUCTION excursion, jaw locking, and noise at the joint with movement.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Imaging Live Drosophila Brain with Two-Photon Fluorescence Microscopy Syeed Ehsan Ahmed University of Texas at El Paso, [email protected]
    University of Texas at El Paso DigitalCommons@UTEP Open Access Theses & Dissertations 2017-01-01 Imaging Live Drosophila Brain With Two-Photon Fluorescence Microscopy Syeed Ehsan Ahmed University of Texas at El Paso, [email protected] Follow this and additional works at: https://digitalcommons.utep.edu/open_etd Part of the Biophysics Commons, and the Optics Commons Recommended Citation Ahmed, Syeed Ehsan, "Imaging Live Drosophila Brain With Two-Photon Fluorescence Microscopy" (2017). Open Access Theses & Dissertations. 397. https://digitalcommons.utep.edu/open_etd/397 This is brought to you for free and open access by DigitalCommons@UTEP. It has been accepted for inclusion in Open Access Theses & Dissertations by an authorized administrator of DigitalCommons@UTEP. For more information, please contact [email protected]. IMAGING LIVE DROSOPHILA BRAIN WITH TWO-PHOTON FLUORESCENCE MICROSCOPY SYEED EHSAN AHMED Master’s Program in Physics APPROVED: Chunqiang Li, Ph.D., Chair Cristian E. Botez, Ph.D. Chuan Xiao, Ph.D. Charles Ambler, Ph.D. Dean of the Graduate School Copyright © by Syeed Ehsan Ahmed 2017 Dedication Dedicated to my beloved family and friends. Thank you for believing in me and helping me throughout my journey. IMAGING LIVE DROSOPHILA BRAIN WITH TWO-PHOTON FLUORESCENCE MICROSCOPY by SYEED EHSAN AHMED, B.Sc. in Physics THESIS Presented to the Faculty of the Graduate School of The University of Texas at El Paso in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE Department of Physics THE UNIVERSITY OF TEXAS AT EL PASO August 2017 ACKNOWLEDGEMENTS All praise and worthiness goes to Almighty Merciful Allah who has given me the opportunity, strength and ability to complete this work.
    [Show full text]
  • Arxiv:2001.11604V2 [Cs.PL] 6 Sep 2020 of Trigger Conditions, Having an in Situ Infrastructure That Simplifies Results They Desire
    DIVA: A Declarative and Reactive Language for in situ Visualization Qi Wu* Tyson Neuroth† Oleg Igouchkine‡ University of California, Davis, University of California, Davis, University of California, Davis, United States United States United States Konduri Aditya§ Jacqueline H. Chen¶ Kwan-Liu Ma|| Indian Institute of Science, India Sandia National Laboratories, University of California, Davis, United States United States ABSTRACT for many applications. VTK [61] also partially adopted this ap- The use of adaptive workflow management for in situ visualization proach, however, VTK is designed for programming unidirectional and analysis has been a growing trend in large-scale scientific simu- visualization pipelines, and provides limited support for highly dy- lations. However, coordinating adaptive workflows with traditional namic dataflows. Moreover, the synchronous dataflow model is procedural programming languages can be difficult because system somewhat difficult to use and does not always lead to modular pro- flow is determined by unpredictable scientific phenomena, which of- grams for large scale applications when control flows become com- ten appear in an unknown order and can evade event handling. This plicated [19]. Functional reactive programming (FRP) [19,24,48,53] makes the implementation of adaptive workflows tedious and error- further improved this model by directly treating time-varying values prone. Recently, reactive and declarative programming paradigms as first-class primitives. This allowed programmers to write reac- have been recognized as well-suited solutions to similar problems in tive programs using dataflows declaratively (as opposed to callback other domains. However, there is a dearth of research on adapting functions), hiding the mechanism that controls those flows under these approaches to in situ visualization and analysis.
    [Show full text]
  • Gelred™& Gelgreen™
    Glowing Products for ScienceTM GelRed™& GelGreen™ www.biotium.com Safe and sensitive nucleic acid gel stains designed to replace the highly toxic ethidium bromide (EtBr). Developed by G scientists at Biotium, GelRed™ and GelGreen™ are superior to EtBr and other SYBR® Safe GelRed™ GelGreen™ EtBr alternatives by having a combination of low toxicity, high sensitivity and exceptional stability. EtBr has been the predominant dye used for nucleic acid gel staining for decades mutagenic chemical. The safety hazard and costs associated with decontamination and waste disposal can ultimately make the dye expensive and inconvenient to use. For this reason, alternative gel stains, such as SYBR® dyes, have become commercially available Figure 2. GelRed™ and GelGreen™ gel stains are safer because they cannot penetrate cell in recent years. While these alternative dyes have reduced mutagenicity membranes to bind DNA in living cells. HeLa cells were incubated at 37oC with 1X SYBR® Safe, sensitivity and stability. For example, SYBR® Safe has very limited sensitivity while GelGreen™ or GelRed™, respectively. Images were taken following incubation with dye for 30 SYBR® Green and SYBR® Gold are much less stable than EtBr. SYBR® dyes also enter SYBR® Safe rapidly entered cells and stained nuclei. GelRed™ and GelGreen™ were unable cells rapidly to stain mitochondria and nuclear DNA, making it more likely for the dyes to be harmful to cells. Indeed, SYBR® Green I has been shown to strongly potentiate DNA was observed in dead cells present sporadically in the cultures, as is observed with other non- mutation caused by UV light and other mutagens (Ohta, et al.
    [Show full text]